Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.42 |
| ▸ | ADK | P55263 | 6/20 | 0.36 |
| ▸ | POLRMT | O00411 | 1/20 | 0.35 |
| ▸ | ENTPD1 | P49961 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24339857 | 1.00 | TMPRSS2 (0.42) | TMPRSS2ADKPOLRMTENTPD1 | |
| SCHEMBL24407353 | 1.00 | TMPRSS2 (0.42) | TMPRSS2ADKPOLRMTENTPD1 | |
| SCHEMBL24340365 | 1.00 | TMPRSS2 (0.42) | TMPRSS2ADKPOLRMTENTPD1 | |
| SCHEMBL25956367 | 1.00 | TMPRSS2 (0.42) | TMPRSS2ADKPOLRMTENTPD1 | |
| SCHEMBL24339537 | 1.00 | TMPRSS2 (0.42) | TMPRSS2ADKPOLRMTENTPD1 | |
| SCHEMBL24339481 | 1.00 | TMPRSS2 (0.42) | TMPRSS2ADKPOLRMTENTPD1 | |
| SCHEMBL24339534 | 1.00 | TMPRSS2 (0.42) | TMPRSS2ADKPOLRMTENTPD1 | |
| SCHEMBL24304364 | 0.98 | TMPRSS2 (0.42) | TMPRSS2ADKPOLRMT | |
| SCHEMBL25967624 | 0.98 | TMPRSS2 (0.42) | TMPRSS2ADKPOLRMT | |
| SCHEMBL25968060 | 0.98 | TMPRSS2 (0.42) | TMPRSS2ADKPOLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12208110-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-11963967-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-4228685-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230248753-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230248753-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20220143052-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2022-05-12 | — | — | US | disclosed |
| US-20220143052-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2022-05-12 | — | — | US | disclosed |
| WO-2022081973-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081973-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143052-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | TMPRSS2 320/4885ADK 1209/4885POLRMT 361/4885 |
| US-12208110-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS1, SGMS2 | TMPRSS2 162/4885ADK 2196/4885POLRMT 455/4885 |
| US-20230248753-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | TMPRSS2 320/4885ADK 1209/4885POLRMT 361/4885 |
| US-11963967-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | TMPRSS2 320/4885ADK 1209/4885POLRMT 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.